Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07129187) titled 'SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response' on Aug. 1.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Chuan Wang
Condition:
Early Breast Cancer
HER2 + Breast Cancer
Stage II Breast Cancer
Stage III Breast Cancer
Intervention:
Drug: SHR-A1811
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 2025
Target Sample Size: 30
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07129187
Published by HT Digit...